{"id":"peg-asparaginase-at-two-weeks-interval","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Coagulopathy/thrombosis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL2108989","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Leukemic blasts, particularly in acute lymphoblastic leukemia (ALL), are dependent on exogenous asparagine for protein synthesis and cannot produce sufficient amounts endogenously. By depleting circulating asparagine, the drug selectively inhibits protein synthesis in leukemic cells while sparing normal cells that can synthesize asparagine. PEGylation extends the drug's half-life and reduces immunogenicity compared to native asparaginase.","oneSentence":"PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:02.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy"}]},"trialDetails":[{"nctId":"NCT00819351","phase":"PHASE3","title":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":650}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oncaspar (PEG-Asparaginase)"],"phase":"phase_3","status":"active","brandName":"PEG Asparaginase at two weeks interval","genericName":"PEG Asparaginase at two weeks interval","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine. Used for Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}